ALIPAY
21.1.2023 19:06:40 CET | Business Wire | Press release
Over 10 million brands and merchants in China joined Alipay’s signature annual Five Fortune Card Collection campaign for the 2023 Chinese New Year, ramping up digital efforts to attract and engage mobile-savvy consumers, as Chinese consumers gear up for the most important festival of the year.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230121005044/en/
A user trying to collect a fortune card by scanning the Chinese character “fu” with AR scan feature in Alipay app (Photo: Business Wire)
This year’s campaign, from January 10, 2023 to January 21, attracted more than 30,000 blue chip and emerging international and domestic brands and over 10 million small and micro business participants seeking to enhance their interaction with Chinese consumers in anticipation of the Spring Festival. This represented a nearly 30 times increase in the number of brands that participated in the campaign last year.
“As an open platform, Alipay is committed to opening up products and technologies to facilitate merchants’ digital transformation. We have also introduced Five Fortune Card IP-related resources to our partners,” said Yongming He, General Manager of the Alipay Ecosystem Development Business Unit and Vice President of Ant Group. “We are glad to see a growing number of brands and merchants participating in the Alipay Five Fortune Card Collection campaign to enhance engagement with users and improve operational efficiency by leveraging digital tools, including mini program and livestreaming, on the Alipay platform.”
Initially launched in 2015, Alipay's Five Fortune Card Collection campaign is an annual event before the Chinese New Year. Users collect digital fortune cards by using the Alipay app's AR scan feature and participating in merchant campaigns, among various ways to win a fortune card. These cards represent good wishes and can be converted into monetary rewards.
This year, for the first time, users can receive a limited-edition digital collectible featuring Chinese intangible cultural heritage, including shadow puppetry, paper-cut and copper sculpture, after successfully obtaining five fortune cards in the campaign.
Users can win a fortune card when they scan the red envelope QR code each time at the outlets of the 10 million participating merchants. They may also obtain cards by logging into Alipay mini programs or by watching livestreams of more than 30,000 participating brands on Alipay. Through these livestreams, brands distributed fortune cards to participants, introduced their products and services, and gave out preferential benefits to build connections with mobile-savvy Chinese consumers.
Merchants and brands have seen significant digital engagement through their participation in the Alipay campaign, with millions of views from livestreaming. On January 11, No. 1 Job Club, a job search service provider, saw 20 million visits to their livestreaming on Alipay platform. On the same day, Yunchongbao, a pet service provider, witnessed 50 million visits to their Alipay livestream. And on January 15, the NBA attracted over 12 million visits to their Alipay livestream which was moderated by several local basketball influencers. These numbers demonstrate the success of the campaign in attracting digital participation from merchants and brands, as reflected in the large livestream audience engagement on the Alipay platform.
Pop-Mart, a culture and entertainment company that is best known for art and collectible toys who introduced the idea of "blind box”, attracted three million visits to their Alipay mini-program six days into the campaign, with its transaction volume through the Alipay platform increasing 300% compared with that of last month.
About Alipay
In the evolving digital era, Alipay has transformed from a trusted payment tool to an open platform for businesses, institutions, service providers, and other partners. Business partners in various industries utilize Alipay to offer consumers a safe and convenient payment experience. Through digital operations on the Alipay platform, business partners can communicate and provide various commercial and daily life digital services for their clients via Alipay mini programs, lifestyle accounts, and IoT, along with other tools available. Currently, there have been over 80 million businesses serving more than one billion consumers via Alipay’s open platform services.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230121005044/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom